Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
Avelumab Significantly Improves PFS Vs Chemo in dMMR/MSI-H Metastatic CRC
October 13th 2023Data from the phase 2 SAMCO-PRODIGE 54 trial may support the use of immune checkpoint inhibitors over standard second-line therapy in mismatch repair–deficient and/or microsatellite instability–high metastatic colorectal cancer.
Ibrutinib Combo Improves PFS Vs Chlorambucil Combo in CLL Genomic Subgroups
October 6th 2023Patients receiving ibrutinib plus venetoclax for chronic lymphocytic leukemia appear to experience improved overall survival at 46 months compared with those receiving chlorambucil plus obinutuzumab in the phase 3 GLOW study.
Amivantamab Significantly Improves PFS Vs Chemotherapy in EGFR+ NSCLC
October 4th 2023Investigators will present overall survival and objective response data from the phase 3 MARIPOSA-2 trial assessing amivantamab in EGFR exon 19 deletion–positive non–small cell lung cancer at a future scientific meeting.